A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Thursday, 7 February 2013
€196 million pan-European drug discovery platform launched Large pharmaceutical companies join forces with small and medium-sized enterprises (SMEs) and academia in an IMI-supported public private partnership (PPP) to enhance early drug discovery and so address the ever-increasing need for innovative therapeutics to tackle unmet medical needs
Friday, 25 January 2013
LDC forms drug discovery alliance with AstraZeneca Dortmund, January 24, 2013 – The Lead Discovery Center GmbH (LDC) and AstraZeneca have joined forces to discover new medicines for the treatment of human diseases with high unmet medical need.
Tuesday, 15 January 2013
AstraZeneca announces changes to Senior Executive Team AstraZeneca today unveiled changes to its executive leadership team. The new, expanded membership of AstraZeneca’s Senior Executive Team, which comes into effect immediately, includes increased representation of the company’s scientific expertise, key products and key markets.
Monday, 14 January 2013
AstraZeneca and Vanderbilt University collaborate to develop novel treatments for major brain disorders AstraZeneca and Vanderbilt University collaborate to develop novel treatments for major brain disorders.
Thursday, 3 January 2013
Cellular Dynamics announces agreement with AstraZeneca on use of iPSC-derived human cells in drug discovery research Cellular Dynamics International, Inc. (CDI) today announced a Center of Excellence agreement with AstraZeneca to accelerate the pace of drug discovery through the use of human induced pluripotent stem cell (iPSC) lines and tissue cells.
Thursday, 27 December 2012
CytImmune and AstraZeneca to Research Potential New Nanomedicine Rockville, MD and Waltham, MA –December 27, 2012-CytImmune and AstraZeneca have entered into an agreement to study the feasibility of a new cancer nanomedicine that will bind an oncology compound from AstraZeneca to CytImmune’s CYT-6091 nanomedicine platform.
Thursday, 20 December 2012
AstraZeneca and LegoChem Biosciences announce collaboration on treatment of antibiotic-resistant bacterial infections AstraZeneca has entered into a research and development option & license agreement with LegoChem Biosciences to develop a novel antibiotic to treat drug-resistant bacterial infections.
Tuesday, 18 December 2012
AstraZeneca and Fudan University sign research collaboration in China AstraZeneca today announced the signing of a research collaboration with Fudan University, one of China’s leading academic institutions in the area of cardiovascular diseases (CVDs), a leading cause of death in China and worldwide.
Tuesday, 11 December 2012
AstraZeneca and Isis Pharmaceuticals form strategic alliance on RNA therapeutics for cancer AstraZeneca and Isis Pharmaceuticals, Inc.  today announced a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets.
Tuesday, 11 December 2012
New Tuberculosis drug trial begins in South Africa Case Western Reserve University and AstraZeneca partner to test novel therapy